10 Best Long Term Growth Stocks to Buy According to Billionaires

7. Insmed Incorporated (NASDAQ:INSM)

5-Year Revenue Growth: ~21.6%

Number of Billionaire Investors: 14

Number of Hedge Funds: 72

Insmed Incorporated (NASDAQ:INSM) develops and commercializes therapies for patients with serious and rare diseases. Analyst Andrew Fein from H.C. Wainwright reiterated a “Buy” rating on the company’s stock with the price objective of $90.00. The analyst’s rating is backed by a combination of factors demonstrating the company’s growth potential and market position. As per the analyst, looking ahead, the potential market for brensocatib in treating Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) provides a growth opportunity. Notably, the Phase 2b BiRCh study of brensocatib in patients with chronic rhinosinusitis without nasal polyps (CRSsNP) remains on track to report topline results by 2025 end.

Insmed Incorporated (NASDAQ:INSM)’s success throughout all the areas of business in 2024—mainly in the delivery of positive data from the landmark Phase 3 ASPEN study of brensocatib in bronchiectasis—placed it to potentially reach several other patients suffering from serious diseases and resulted in strong value creation. Notably, Brensocatib can become the first and only approved treatment for bronchiectasis and the first in a new class of medicines called dipeptidyl peptidase 1 (DPP1) inhibitors for treating neutrophil-mediated diseases.

Baron Funds, an investment management company, released its Q4 2024 investor letter. Here is what the fund said:

“We added to the position in Insmed Incorporated (NASDAQ:INSM), a biopharmaceutical company with three lead drugs that we believe could collectively generate over $8 billion of peak sales. The company expects to launch Brensocatib for non-cystic fibrosis bronchiectasis (NCFBE) in 2025. In a Phase 3 clinical trial, the drug achieved a 20% reduction in pulmonary exacerbations and an improvement in lung function. We think there could be as many as 500,000 NCFBE patients in the U.S. and that the disease is widely underdiagnosed (or rather, mis-diagnosed as asthma/COPD) given there are no approved treatments. In addition, brensocatib is a pipeline in a product. It’s a DPP1 inhibitor that is very potent against neutrophil serine proteases. Neutrophil serine protease activity is key in the cycle of inflammation and lung damage in bronchiectasis and is also known to play an important role in chronic rhinosinusitis without nasal polyps. In addition, another drug, Arikayce is on-market to treat refractory MAC lung disease and will likely get a front-line label with Phase 3 data expected in 2025. A third drug candidate, TPIP, is in the early stage but shows impressive efficacy/safety in PAH/PH-ILD and could be a best-in-class option.”